Status:
COMPLETED
Efficacy of Naltrexone Treatment as Augmentation to SSRI in OCD Patients
Lead Sponsor:
Sheba Medical Center
Conditions:
Obsessive Compulsive Disorder
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Assessing the efficacy of Naltrexone as augmentation to SSRI in patients with OCD
Eligibility Criteria
Inclusion
- Diagnosis of OCD
- Treatment with SSRI for at least 10 weeks with no response
Exclusion
- Suffering from any medical condition
- treatment with opiates
- chronic use of drugs
- Hepatitis or other liver related diseases
- Incapability to sign an informed consent
Key Trial Info
Start Date :
January 1 2002
Trial Type :
INTERVENTIONAL
End Date :
December 1 2004
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00234689
Start Date
January 1 2002
End Date
December 1 2004
Last Update
January 30 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chaim Sheba Medical Center
Ramat Gan, Israel, 52621